Dr. Muhammad Imtiaz Ashraf did his PhD in 2012 in the laboratory of Prof. Jakob Troppmair, Dept. of Visceral-, Transplant- and Thoracic Surgery, Medical University of Innsbruck, Austria. In his doctoral thesis, he identified a novel and crucial role of p38MAPK in the regulation of ischemia reperfusion injury, in part, through its effects on mitochondrial functions. From 2012 to 2015, he was working in the same department as a post-doctoral scientist under supervision of Prof. Felix Aigner. There, he investigated the function role of Lcn2, an emerging biomarker of acute renal injury and graft rejection, in the course of renal allograft rejection. Since he moved to the department of surgery, Charite, Berlin in 2015, he has been involved in several projects aimed at elucidating critical mechanisms of renal allograft rejection and developing novel approaches for pre-transplant testing of solid organs. In particular, he teamed up with Prof. Felix Aigner and Prof Igor M. Sauer within CRC-Renoprotection (1365) on defining molecular and cellular mechanisms of rLcn2-mediated protection of the renal grafts. He has long-standing expertise in pre-clinical models of organ transplantation, including kidney and heart transplantation in the mouse and rat models.
His major current and future research interests aim at;